Shajahan-Haq AN - Search Results

1

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells.

Scheidemann ER, Demas DM, Hou C, Ma J, He W, Sharma G, Schultz E, Weilbaecher KN, Shajahan-Haq AN. Scheidemann ER, et al. Among authors: shajahan haq an. Mol Carcinog. 2024 Feb;63(2):209-223. doi: 10.1002/mc.23646. Epub 2023 Oct 11. Mol Carcinog. 2024. PMID: 37818798

2

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.

Scheidemann ER, Shajahan-Haq AN. Scheidemann ER, et al. Among authors: shajahan haq an. Int J Mol Sci. 2021 Nov 14;22(22):12292. doi: 10.3390/ijms222212292. Int J Mol Sci. 2021. PMID: 34830174 Free PMC article. Review.

3

MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.

Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, Eltayeb AE, Demas DM, Warri AM, Facey CO, Hilakivi-Clarke LA, Clarke R. Shajahan-Haq AN, et al. Mol Cancer. 2014 Oct 23;13:239. doi: 10.1186/1476-4598-13-239. Mol Cancer. 2014. PMID: 25339305 Free PMC article.

4

Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer.

Demas DM, Demo S, Fallah Y, Clarke R, Nephew KP, Althouse S, Sandusky G, He W, Shajahan-Haq AN. Demas DM, et al. Front Oncol. 2019 Aug 2;9:686. doi: 10.3389/fonc.2019.00686. eCollection 2019. Front Oncol. 2019. PMID: 31428575 Free PMC article.

5

Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition.

He W, Demas DM, Conde IP, Shajahan-Haq AN, Baumann WT. He W, et al. Among authors: shajahan haq an. J R Soc Interface. 2020 Aug;17(169):20200339. doi: 10.1098/rsif.2020.0339. Epub 2020 Aug 26. J R Soc Interface. 2020. PMID: 32842890 Free PMC article.

6

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors.

Fallah Y, Demas DM, Jin L, He W, Shajahan-Haq AN. Fallah Y, et al. Among authors: shajahan haq an. Front Oncol. 2021 Jul 1;11:681530. doi: 10.3389/fonc.2021.681530. eCollection 2021. Front Oncol. 2021. PMID: 34277427 Free PMC article.

7

Mathematically Modeling the Effect of Endocrine and Cdk4/6 Inhibitor Therapies on Breast Cancer Cells.

He W, Shajahan-Haq AN, Baumann WT. He W, et al. Among authors: shajahan haq an. Methods Mol Biol. 2023;2634:337-355. doi: 10.1007/978-1-0716-3008-2_16. Methods Mol Biol. 2023. PMID: 37074587

8

Modeling breast cancer proliferation, drug synergies, and alternating therapies.

He W, Demas DM, Shajahan-Haq AN, Baumann WT. He W, et al. Among authors: shajahan haq an. iScience. 2023 Apr 23;26(5):106714. doi: 10.1016/j.isci.2023.106714. eCollection 2023 May 19. iScience. 2023. PMID: 37234088 Free PMC article.

9

MYC-Driven Pathways in Breast Cancer Subtypes.

Fallah Y, Brundage J, Allegakoen P, Shajahan-Haq AN. Fallah Y, et al. Biomolecules. 2017 Jul 11;7(3):53. doi: 10.3390/biom7030053. Biomolecules. 2017. PMID: 28696357 Free PMC article. Review.

10

CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.

Lynce F, Shajahan-Haq AN, Swain SM. Lynce F, et al. Pharmacol Ther. 2018 Nov;191:65-73. doi: 10.1016/j.pharmthera.2018.06.008. Epub 2018 Jun 19. Pharmacol Ther. 2018. PMID: 29933034 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters